Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

Parkinsonism and Related Disorders

Volumn 16, Issue 3, 2010, Pages 218-221

  Puente, V ^a   De Fabregues, O ^b   Oliveras, C ^a   Ribera, G ^b   Pont Sunyer, C ^a   Vivanco, R ^a   Cucurella, G ^a   Giralt, E ^a   Delgado, T ^b   Garcia, C ^b   Seoane, A ^a   Campo, R ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

Author keywords

Continuous intraduodenal levodopa infusion; Duodopa; Fluctuations; Monotherapy; Parkinson's disease; Quality of life

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; RASAGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE CONTROL; DISEASE SEVERITY; DRUG INFUSION; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; DISABILITY EVALUATION; DUODENUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 76849106479     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2009.07.015     Document Type: Article

References (12)

1. Agid Y., Ahlshog E., Albanese A., Calne D., Chase T., De Yébenes J., et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 14 (1995) 911-913
2. Marsden C.D., Parkes J.D., and Quinn N. Fluctuations disability in Parkinson's disease-clinical aspects. In: Masden C.D., and Fahn S. (Eds). Movement disorders (1982), Butterworth, London 96-122
3. Tolosa E., Martin W.E., Cohen H.P., and Jacobson R.L. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 25 (1975) 177-183
4. Kurlan R., Rothfield K.P., Woodward W.R., Nutt J.G., Miller C., Lichter D., et al. Erratic gastric emptying may cause "random" fluctuations of parkinsonian mobility. Neurology 38 (1988) 419-421
5. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernäs H., Nyström C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26 (2003) 156-163
6. Nyholm D., Nilsson R., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
7. Bredberg E., Nilsson D., Johansson K., Aquilonius S.M., Johnels B., Nystrom C., et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 45 (1993) 117-122
8. National Parkinson's Foundation. Hoehn and Yahr staging of Parkinson's disease, Unified Parkinson disease rating scale (UPDRS), and Schwab and England activities of daily living. Available at: http://www.parkinson.org/NETCOMMUNITY/Page.aspx?pid=367&srcid=202 [accessed 29.12.07].
9. Department of Public Health, University of Oxford. PDP-39 Parkinson's disease questionnaire. Available at: http://www.publichealth.oxac.uk/units/hsru/PDQ.
10. Schwab R.S., and England A.C. Rn third symposium on Parkinson's disease (1969), E and S. Livingstone, Edinburgh p. 152-57
11. Antonioni A., Isaias I.U., Canesi M., Zibetti M., Manciani F., Manfredi L., et al. Duodenal levodopa infusión for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22 (2007) 1145-1149
12. Kurth M.C., Tetrud J.W., Tanner C.M., Irwin I., Stebbins G.T., Goetz C.G., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 43 (1993) 1698-1703